253 related articles for article (PubMed ID: 26379028)
1. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Chou WC; Hsu SC; Ko BS; Tien HF
J Formos Med Assoc; 2022 Mar; 121(3):643-651. PubMed ID: 34246509
[TBL] [Abstract][Full Text] [Related]
3. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
5. Decorin in human oral cancer: a promising predictive biomarker of S-1 neoadjuvant chemosensitivity.
Kasamatsu A; Uzawa K; Minakawa Y; Ishige S; Kasama H; Endo-Sakamoto Y; Ogawara K; Shiiba M; Takiguchi Y; Tanzawa H
Biochem Biophys Res Commun; 2015 Jan; 457(1):71-6. PubMed ID: 25550184
[TBL] [Abstract][Full Text] [Related]
6. The effect of glucocorticoid on the synthesis of biglycan and decorin in human osteoblasts and bone marrow stromal cells.
Kimoto S; Cheng SL; Zhang SF; Avioli LV
Endocrinology; 1994 Dec; 135(6):2423-31. PubMed ID: 7988427
[TBL] [Abstract][Full Text] [Related]
7. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
8. Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
Nemani N; Santo L; Eda H; Cirstea D; Mishima Y; Patel C; O'Donnell E; Yee A; Raje N
J Bone Miner Res; 2015 Mar; 30(3):465-70. PubMed ID: 25407518
[TBL] [Abstract][Full Text] [Related]
9. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y; Luetkens T; Kobold S; Hildebrandt Y; Gordic M; Lajmi N; Meyer S; Bartels K; Zander AR; Bokemeyer C; Kröger N; Atanackovic D
Exp Hematol; 2010 Oct; 38(10):860-7. PubMed ID: 20619313
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
12. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
[TBL] [Abstract][Full Text] [Related]
13. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
[TBL] [Abstract][Full Text] [Related]
14. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract][Full Text] [Related]
15. Mast cell tryptase stimulates production of decorin by human testicular peritubular cells: possible role of decorin in male infertility by interfering with growth factor signaling.
Adam M; Schwarzer JU; Köhn FM; Strauss L; Poutanen M; Mayerhofer A
Hum Reprod; 2011 Oct; 26(10):2613-25. PubMed ID: 21791437
[TBL] [Abstract][Full Text] [Related]
16. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
17. Decorin inhibits the insulin-like growth factor I signaling in bone marrow mesenchymal stem cells of aged humans.
Wong TH; Chen TY; Tseng KY; Chen ZY; Chen CH; Lin FH; Wu HM; Lin S
Aging (Albany NY); 2020 Nov; 13(1):578-597. PubMed ID: 33257596
[TBL] [Abstract][Full Text] [Related]
18. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.
Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L
Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
20. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
